Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03436862
Title Nivolumab as Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Hodgkin Lymphoma at Risk of Relapse or Progression
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors SCRI Development Innovations, LLC
Indications

Hodgkin's lymphoma

Therapies

Nivolumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.